{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T16:41:18Z","timestamp":1789922478097,"version":"4.0.1"},"reference-count":33,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,8,31]],"date-time":"2020-08-31T00:00:00Z","timestamp":1598832000000},"content-version":"am","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100013226","name":"Les Laboratories Pierre Fabre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007744","name":"Association pour le D\u00c3\u00a9veloppement et l'Organisation de la Recherche en Pneumologie et sur le Sommeil","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007744","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.therap.2019.02.001","type":"journal-article","created":{"date-parts":[[2019,2,25]],"date-time":"2019-02-25T11:45:21Z","timestamp":1551095121000},"page":"459-468","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Six-year survival study after myocardial infarction: The EOLE prospective cohort study. Long-term survival after MI"],"prefix":"10.1016","volume":"74","author":[{"given":"C\u00e9cile","family":"Droz-Perroteau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Blin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Dureau-Pournin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Danchin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Tricoire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Paillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge","family":"Hercberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"Guize","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estelle","family":"Guiard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Ma\u00efzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Agn\u00e8s","family":"Bernard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"B\u00e9nichou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1212-2817","authenticated-orcid":false,"given":"Nicholas","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9205","key":"10.1016\/j.therap.2019.02.001_bib0170","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0140-6736(99)11180-2","article-title":"Estimation of contribution of changes in classic risk factors to trends in coronary-event rates across the WHO MONICA Project populations","volume":"355","author":"Kuulasmaa","year":"2000","journal-title":"Lancet"},{"issue":"9205","key":"10.1016\/j.therap.2019.02.001_bib0175","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/S0140-6736(99)11181-4","article-title":"Estimation of contribution of changes in coronary care to improving survival, event rates, and coronary heart disease mortality across the WHO MONICA Project populations","volume":"355","author":"Tunstall-Pedoe","year":"2000","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.therap.2019.02.001_bib0180","first-page":"1300","article-title":"Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension","volume":"15","author":"Py\u00f6r\u00e4l\u00e4","year":"1994","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.therap.2019.02.001_bib0185","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S0195-668X(02)00618-8","article-title":"Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology","volume":"24","author":"Van de Werf","year":"2003","journal-title":"Eur Heart J"},{"issue":"23","key":"10.1016\/j.therap.2019.02.001_bib0190","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1093\/eurheartj\/ehn416","article-title":"Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology","volume":"29","author":"Van de Werf","year":"2008","journal-title":"Eur Heart J"},{"issue":"13","key":"10.1016\/j.therap.2019.02.001_bib0195","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1001\/jama.2012.12559","article-title":"Beta-blocker use and clinical outcomes in stable outpatients with and without coronary artery disease","volume":"308","author":"Bangalore","year":"2012","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.therap.2019.02.001_bib0200","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/j.ahj.2005.01.058","article-title":"Impact of combined secondary prevention therapy after myocardial infarction: data from a nationwide French registry","volume":"150","author":"Danchin","year":"2005","journal-title":"Am Heart J"},{"issue":"20","key":"10.1016\/j.therap.2019.02.001_bib0205","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1093\/eurheartj\/ehs215","article-title":"ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation","volume":"33","author":"Steg","year":"2012","journal-title":"Eur Heart J"},{"issue":"10","key":"10.1016\/j.therap.2019.02.001_bib0210","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1093\/oxfordjournals.eurheartj.a015136","article-title":"A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results, EUROASPIRE Study Group. European Action on Secondary Prevention through Intervention to Reduce Events","volume":"18","author":"EuroASPIRE Study Group. EUROASPIRE","year":"1997","journal-title":"Eur Heart J"},{"issue":"7","key":"10.1016\/j.therap.2019.02.001_bib0215","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1053\/euhj.2001.2610","article-title":"Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme","volume":"22","author":"EuroASPIRE II Study Group","year":"2001","journal-title":"Eur Heart J"},{"issue":"2","key":"10.1016\/j.therap.2019.02.001_bib0220","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/HJR.0b013e3283294b1d","article-title":"EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries","volume":"16","author":"Kotseva","year":"2009","journal-title":"Eur J Cardiovasc Prev Rehabil"},{"issue":"9667","key":"10.1016\/j.therap.2019.02.001_bib0225","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S0140-6736(09)60330-5","article-title":"Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries","volume":"373","author":"Kotseva","year":"2009","journal-title":"Lancet"},{"issue":"15","key":"10.1016\/j.therap.2019.02.001_bib0230","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1136\/hrt.2009.184853","article-title":"Six-month survival benefits associated with clinical guideline recommendations in acute coronary syndromes","volume":"96","author":"Chew","year":"2010","journal-title":"Heart"},{"issue":"2","key":"10.1016\/j.therap.2019.02.001_bib0235","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s10654-007-9212-4","article-title":"Use of recommended medications after myocardial infarction in Austria","volume":"23","author":"Winkelmayer","year":"2008","journal-title":"Eur J Epidemiol"},{"issue":"3","key":"10.1016\/j.therap.2019.02.001_bib0240","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/pds.4171","article-title":"Comparative effectiveness of recommended versus less intensive drug combinations in secondary prevention of acute coronary syndrome","volume":"26","author":"Bezin","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.therap.2019.02.001_bib0245","doi-asserted-by":"crossref","first-page":"i4801","DOI":"10.1136\/bmj.i4801","article-title":"Beta blockers and mortality after myocardial infarction in patients without heart failure: multicentre prospective cohort study","volume":"354","author":"Puymirat","year":"2016","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.therap.2019.02.001_bib0250","doi-asserted-by":"crossref","first-page":"e004356","DOI":"10.1161\/CIRCOUTCOMES.117.004356","article-title":"Clinical events after discontinuation of beta-blockers in patients without heart failure optimally treated after acute myocardial infarction: a cohort study on the French healthcare databases","volume":"11","author":"Neumann","year":"2018","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"6","key":"10.1016\/j.therap.2019.02.001_bib0255","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1161\/CIRCOUTCOMES.114.001073","article-title":"Beta-blockers and cardiovascular events in patients with and without myocardial infarction: post hoc analysis from the CHARISMA trial","volume":"7","author":"Bangalore","year":"2014","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"22","key":"10.1016\/j.therap.2019.02.001_bib0260","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1016\/j.jacc.2017.03.578","article-title":"Beta-blockers and mortality after acute myocardial infarction in patients without heart failure or ventricular dysfunction","volume":"69","author":"Dondo","year":"2017","journal-title":"J Am Coll Cardio"},{"issue":"6921","key":"10.1016\/j.therap.2019.02.001_bib0265","first-page":"81","article-title":"Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients","volume":"308","author":"Antiplatelet Trialists Collaboration","year":"1994","journal-title":"Antiplatelet Trialists\u2019 Collaboration BMJ"},{"issue":"7329","key":"10.1016\/j.therap.2019.02.001_bib0270","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","article-title":"Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients","volume":"324","author":"Antithrombotic Trialists Collaboration","year":"2002","journal-title":"BMJ"},{"issue":"9678","key":"10.1016\/j.therap.2019.02.001_bib0275","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","article-title":"Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials","volume":"373","author":"Antithrombotic Trialists Collaboration","year":"2009","journal-title":"Lancet"},{"issue":"6\u00a0Pt 2","key":"10.1016\/j.therap.2019.02.001_bib0280","article-title":"The aspirin myocardial infarction study: final results. The Aspirin Myocardial Infarction Study research group","volume":"62","author":"AMIS Research Group","year":"1980","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.therap.2019.02.001_bib0285","article-title":"A clinical trial of the secondary prevention of reinfarction with low dose aspirin","volume":"19","author":"Chen","year":"1991","journal-title":"Zhonghua Xin Xue Guan Bing Za Zhi"},{"issue":"Suppl. 22","key":"10.1016\/j.therap.2019.02.001_bib0290","first-page":"S691","article-title":"Update on aspirin in the treatment and prevention of cardiovascular disease","volume":"8","author":"Hennekens","year":"2002","journal-title":"Am J Manag Care"},{"issue":"3","key":"10.1016\/j.therap.2019.02.001_bib0295","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1056\/NEJMp1213380","article-title":"Aspirin in the secondary prevention of cardiovascular disease","volume":"368","author":"Parekh","year":"2013","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.therap.2019.02.001_bib0300","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1111\/bcp.13291","article-title":"Outcomes in patients after myocardial infarction similar to those of the PEGASUS-TIMI 54 trial: A cohort study in the French national claims database","volume":"83","author":"Blin","year":"2017","journal-title":"Br J Clin Pharmacol"},{"issue":"8","key":"10.1016\/j.therap.2019.02.001_bib0305","first-page":"655","article-title":"Long-term survival in patients with different combinations of evidence-based medications after incident acute myocardial infarction: results from the MONICA\/KORA Myocardial Infarction Registry","volume":"103","author":"Amann","year":"2014","journal-title":"Clin Res Cardiol"},{"issue":"8","key":"10.1016\/j.therap.2019.02.001_bib0310","first-page":"954","article-title":"The national health insurance claims databases in France","volume":"26","author":"Bezin","year":"2017","journal-title":"SNIIRAM and EGB: powerful tools for pharmacoepidemiology. Pharmacoepidemiol Drug Saf"},{"issue":"4","key":"10.1016\/j.therap.2019.02.001_bib0315","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s00228-013-1614-5","article-title":"Use of the recommended drug combination for secondary prevention after a first occurrence of acute coronary syndrome in France","volume":"70","author":"Bezin","year":"2014","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.therap.2019.02.001_bib0320","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1186\/1471-2458-10-242","article-title":"The Nutrinet-Sante Study: a web-based prospective study on the relationship between nutrition and health and determinants of dietary patterns and nutritional status","volume":"10","author":"Hercberg","year":"2010","journal-title":"BMC Public Health"},{"key":"10.1016\/j.therap.2019.02.001_bib0325","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.puhe.2016.10.029","article-title":"Pertinence of electronic death certificates for real-time surveillance and alert, France, 2012\u20132014","volume":"143","author":"Lassalle","year":"2017","journal-title":"Public Health"},{"issue":"2","key":"10.1016\/j.therap.2019.02.001_bib0330","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","volume":"39","author":"Ibanez","year":"2018","journal-title":"Eur Heart J"}],"container-title":["Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595719300320?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595719300320?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T18:53:11Z","timestamp":1758567191000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595719300320"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["S0040595719300320"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2019.02.001","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Six-year survival study after myocardial infarction: The EOLE prospective cohort study. Long-term survival after MI","name":"articletitle","label":"Article Title"},{"value":"Therapies","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.therap.2019.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Soci\u00e9t\u00e9 fran\u00e7aise de pharmacologie et de th\u00e9rapeutique. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}